The growing development in the drugs and technological advancement in the treatment of cluster headache is the major factor encouraging the growth of the global cluster headache treatment market. For instance, in June 2019, Eli Lilly and Co. granted the US Food and Drug Administration (FDA) approval for Emgality (Galcanezumab). The drug that helps in decreasing the frequency of attacks in episodic cluster headache patients. It is the first FDA approved drug for the treatment of Episodic Cluster Headache. It helps in reducing the chances of migraines in cluster headache affected patients. The safety of Emgality was evaluated in three clinical trials that include more than 2,500 patients.